You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

22 Results
Drug
Other Name(s): Tarceva®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Oct 2022
Drug
Other Name(s): Xtandi®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 1969
Drug
Other Name(s): Bosulif®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    erlotinib - Incurable progressive NSCLC, with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
erlotinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2022
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    enzalutamide - For the treatment of metastatic castrate-resistant prostate cancer (mCRPC), based on criteria
Exceptional Access Program
    enzalutamide - For the treatment of high risk non-metastatic castration-resistant prostate cancer (nmCRPC), based on criteria
Exceptional Access Program
    enzalutamide - For the treatment metastatic castration-sensitive prostate cancer (mCSPC), based on criteria
Exceptional Access Program
    enzalutamide - For the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk of metastasis (high-risk BCR), based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
enzalutamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    bosutinib - For the treatment of patients with chronic, accelerated or blast phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML), according to specific criteria.
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bosutinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2024
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - In Combination with Pomalidomide and Dexamethasone for Previously Treated Multiple Myeloma
ODB - General Benefit
    dexamethasone
Exceptional Access Program
    pomalidomide - In combination with bortezomib and dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bortezomib,
dexamethasone,
pomalidomide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    exemestane
Exceptional Access Program
    ribociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
exemestane,
ribociclib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    exemestane
Exceptional Access Program
    palbociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
exemestane,
palbociclib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Drug
Other Name(s): Alunbrig®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jul 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    brigatinib - For the treatment of anaplastic lymphoma kinase-positive locally advanced or metastatic non-small cell lung cancer according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
brigatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2024
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - In Combination with Selinexor and Dexamethasone for Previously Treated Multiple Myeloma
ODB - General Benefit
    dexamethasone
Exceptional Access Program
    selinexor - In combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bortezomib,
dexamethasone,
selinexor
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2024

Pages